Niagen Bioscience (NAGE) Current Assets (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Current Assets of $105.1 million for Q1 2026, up 37.92% year-over-year from $76.2 million in Q1 2025, and up 8.59% quarter-over-quarter from $96.8 million in Q4 2025.
Niagen Bioscience (NAGE) Current Assets (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Current Assets for 14 consecutive years, with $105.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 37.92% year-over-year to $105.1 million; the TTM figure through Mar 2026 stood at $105.1 million (up 37.92% YoY), while the FY2025 annual figure was $96.8 million, up 51.02% from the prior year.
- Current Assets grew to $105.1 million in Q1 2026 per NAGE's latest filing, from $96.8 million in the prior quarter.
- Across five years, Current Assets topped out at $105.1 million in Q1 2026 and bottomed at $37.9 million in Q3 2022.
- Historically, Current Assets has averaged $60.6 million across 5 years, with a median of $49.3 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets slumped 33.53% — and 2025, when it surged 79.57%.
- Niagen Bioscience's Current Assets stood at $46.6 million in 2022, then advanced by 6.37% to $49.5 million in 2023, then gained by 29.41% to $64.1 million in 2024, then jumped by 51.02% to $96.8 million in 2025, then gained by 8.59% to $105.1 million in 2026.
- Business Quant data shows NAGE's Current Assets at $105.1 million in Q1 2026, $96.8 million in Q4 2025, and $93.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 97.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.79 Mn |
| Mar 31, 2026 | 105.12 Mn |
| Dec 31, 2025 | 96.81 Mn |
| Sep 30, 2025 | 93.62 Mn |
| Jun 30, 2025 | 86.68 Mn |
| Mar 31, 2025 | 76.22 Mn |
| Dec 31, 2024 | 64.10 Mn |
| Sep 30, 2024 | 52.13 Mn |
| Jun 30, 2024 | 49.30 Mn |
| Mar 31, 2024 | 48.98 Mn |
| Dec 31, 2023 | 49.53 Mn |
| Sep 30, 2023 | 47.18 Mn |
| Jun 30, 2023 | 46.38 Mn |
| Mar 31, 2023 | 46.57 Mn |
| Dec 31, 2022 | 46.57 Mn |
| Sep 30, 2022 | 37.90 Mn |
| Jun 30, 2022 | 38.51 Mn |
| Mar 31, 2022 | 44.52 Mn |
| Dec 31, 2021 | 48.91 Mn |
| Sep 30, 2021 | 52.84 Mn |